Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imzokitug (BMS-986340) Plus Nivolumab and Chemotherapy in First-Line Advanced Pancreatic Cancer
NCT07226856Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Dec 2025
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imzokitug in pancreatic adenocarcinoma (PDAC), sponsored by Mayo Clinic. Primary endpoints: Incidence of significant adverse events (Safety Run-in) at 28 days and Objective response rate at 6 months. Started Dec 2025; status: recruiting.
02
Drugs
imzokitug
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07226856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07226856.